NCT03425006 2023-09-13
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
University of Pennsylvania
Phase 2 Terminated
Clinical Trials
3 trialsNCT02257619 2018-01-25
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 2 Terminated
NCT02456675 2018-01-12
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
Incyte Corporation
Phase 2 Terminated